Proactive Investors - Run By Investors For Investors

Hikma Pharmaceuticals top mid-cap casualty as Jefferies International downgrades

Jefferies has cut its rating for the FTSE 250-listed firm to ‘underperform’ from ‘hold and chopped its target price to 895p from 1,074p after lowering its earnings per share forecasts
Drugs
In late morning trade, Hikma shares were down 6.5%, or 69.5p at 1,005.5p

Hikma Pharmaceuticals PLC (LON:HIK) was the biggest mid-cap casualty today after US broker Jefferies International downgraded its rating for the generics drugmaker as it thinks the market is likely to be disappointed by the group’s full year outlook.

Jefferies has cut its rating for the FTSE 250-listed firm to ‘underperform’ from ‘hold and chopped its target price to 895p from 1,074p after lowering its earnings per share forecasts.

READ: Jefferies International calls the floor on Hikma Pharma shares following profit warning slide

In late morning trade, Hikma shares were down 6.5%, or 69.5p at 1,005.5p.

In a note to clients, the US broker’s analysts  said: “We take a directional view into FY as believe the street is likely to be disappointed by HIK's FY outlook and we anticipate some Roxane write-downs to impact sentiment.”

They cut their 2018 EPS estimates by around a further 7% after analysing the group’s most recent interim management statement and also assume a more cautious sum-of-the-parts stance.

The analysts noted that Hikma has previously placed the emphasis on cash-flow rather than growth for its branded business as hospitals have been slowing purchases and volatile foreign exchange movements has impacted reported growth.

They believe the market continues to be too bullish for this segment.

View full HIK profile View Profile

Hikma Pharmaceuticals Timeline

Related Articles

researcher filling a tray of samples
Fri
The company has two clinical trials underway and is well funded to achieve its immediate ambitions
1528098797_Biotech-lab.jpg
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use